ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ビマトプロスト

Bimatoprost

HCID 5311027
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
155206-00-1
標準SMILES
CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
InChIKey
AQOKCDNYWBIDND-FTOWTWDKSA-N
分子式
C25H37NO4
平均分子量
415.6 g/mol
単同位体質量
415.27225866

概要

Bimatoprost is a monocarboxylic acid amide. It has a role as an antihypertensive agent and an antiglaucoma drug.

名称と識別子

優先名称
Bimatoprost
IUPAC
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
現地名
ビマトプロスト
英語名
Bimatoprost
分子式
C25H37NO4
分子量
415.57

名称と別名

Bimatoprost155206-00-1LumiganLatisseAGN 192024ProstamideAGN-192024bimatoprostum(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamideDURYSTAQXS94885MZ(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
名称をさらに表示
ビマトプロストビマトプロストビマトプロスト (JAN)ルミガン(5Z)-7-[(1R,2R,3R,5S)-3,5-ジヒドロキシ-2-[(1E,3S)-3-ヒドロキシ-5-フェニルペンタ-1-エン-1-イル]シクロペンチル]-N-エチルヘプタ-5-エンアミドグラッシュビスタ(5Z)-N-エチル-7-[(1R,2R,3R,5S)-2-[(1E,3S)-3-ヒドロキシ-5-フェニル-1-ペンテニル]-3,5-ジヒドロキシシクロペンタン-1-イル]-5-ヘプテンアミドプロスタミド(5Z)-N-エチル-7-[2β-[(1E,3S)-3-ヒドロキシ-5-フェニル-1-ペンテニル]-3α,5α-ジヒドロキシシクロペンタン-1α-イル]-5-ヘプテンアミド(5Z)-N-エチル-7-[(1R)-2β-[(1E,3S)-3-ヒドロキシ-5-フェニル-1-ペンテニル]-3α,5α-ジヒドロキシシクロペンタン-1α-イル]-5-ヘプテンアミドBimabimatoprost powderN-ETHYL-9ALPHA,11ALPHA,15S-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROSTA-5Z, 13E-DIEN-1-AMIDEbimatoprosBimatoprost (W.S)BiMatoprost HOUSE STANDARD

物性

構造計算による物性補完中

XLogP
2.8
極性表面積
89.8 Ų
水素結合供与体数
4
水素結合受容体数
4
回転可能結合数
12
重原子数
30
形式電荷
0
複雑度
541

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
LogP3.2
Solubility · 2 件

soluble in water

1.87e-02 g/L

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Antiglaucoma Agents; Prostaglandins

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Melting Point63-67
Physical DescriptionSolid
Dissociation Constants14.3, - 0.23

物理化学的性質

融点
66 · 66-68°C
沸点
629.8 · 629.8±55.0 °C(Predicted)
比重(密度)
1.145 · 1.145±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · -20°C
溶解性

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H302 (23.8%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P317, P318, P321, P330, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 21 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (23.8%)

毒性情報

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
3
Hazard Classifications
Acute Tox. 4 OralRepr. 1B
ストレージクラス
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

化学と産業

薬理情報

ATC Code · 3 件

S01EE03

S - Sensory organs

QS - Sensory organs

Protein BindingBimatoprost is about 88%-90% bound to plasma proteins.
Pharmacodynamics · 1 件

High intraocular pressure is a major risk factor for glaucoma-related visual field loss. A linear relationship exists between intraocular pressure and the risk of damaging the optic nerve, which can lead to considerable visual impairment. Therefore, conditions such as ocular hypertension and glaucoma can cause dangerous elevations of intraocular pressure. Bimatoprost rapidly decreases intraocular pressure and reduces the risk for visual field loss from ocular hypertension due to various causes. Other effects of this drug may include gradual changes in eyelid pigmentation, changes in iris pigmentation, changes in eyelash pigmentation, growth and thickness. Patients should be informed of these possible effects, especially if this drug is only administered to one eye, which may noticeably change in appearance with bimatoprost treatment.

Mechanism of Action · 1 件

Bimatoprost imitates the effects of prostamides, specifically prostaglandin F2α. Bimatoprost mildly stimulates aqueous humor outflow, relieving elevated intraocular pressure and decreasing the risk of optic nerve damage. It is thought that bimatoprost reduces intraocular pressure (IOP) in humans by causing an increase in outflow of the aqueous humor via the trabecular meshwork and uveoscleral pathways. It achieves the above effects by decreasing tonographic resistance to aqueous humor outflow. Bimatoprost does not affect aqueous humor production.

Biological Half-LifeThe elimination half-life of bimatoprost is approximately 45 minutes.
Metabolism/Metabolites · 1 件

Bimatoprost is hydrolyzed to its active form, bimatoprost acid, in the eye. Bimatoprost undergoes oxidation, N-deethylation, and glucuronidation after it is systemically absorbed, and this leads to the production of various metabolites. In vitro studies show that CYP3A4 is an enzyme that participates in the metabolism of bimatoprost. Despite this, many enzymes and pathways metabolize bimatoprost, therefore, no significant drug-drug interactions are likely to occur. Glucuronidated metabolites comprise most of the excreted drug product in the blood, urine, and feces in rats.

関連反応

9 件
反応記録を作成
HRID 62567 の反応式
HRID 62567反応物として
HRID 422890 の反応式
HRID 422890反応物として
HRID 517405 の反応式
HRID 517405生成物として
HRID 551520 の反応式
HRID 551520反応物として
HRID 591123 の反応式
HRID 591123反応物として
HRID 593414 の反応式
HRID 593414生成物として
HRID 1621277 の反応式
HRID 1621277生成物として
HRID 1621278 の反応式
HRID 1621278生成物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
17-phenyl-tri-norprostaglandin f2α-ethyl amide
17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE
CHEBI:51230DTXSID30895042GANFORT COMPONENT BIMATOPROSTAGN1920245-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide192024, AGN

データベース識別子

CAS
155206-00-1
PubChem CID
5311027
DTXSID
DTXSID30895042
ChEMBL
CHEMBL1200963
ChEBI
CHEBI:51230
UNII
QXS94885MZ
EC Number
642-890-9
Nikkaji
J1.596.089B
クロロホルム(微量)、ジクロロメタン(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
14.25 · 14.25±0.20(Predicted)
色
ホワイトからオフホワイト
BCS Class
3 · 3
安定性
光に敏感
化粧品成分の機能
まつ毛コンディショニング
InChIKey
AQOKCDNYWBIDND-FTOWTWDKSA-N
SMILES
C(NCC)(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CC=C1
CAS データベース
155206 · 155206-00-1(CAS DataBase Reference)

化学的性質

化学的特性Crystalline Solid

FDA Pharmacological Classification · 6 件

QXS94885MZ

BIMATOPROST

Established Pharmacologic Class [EPC] - Prostaglandin Analog

Chemical Structure [CS] - Prostaglandins

Bimatoprost is a Prostaglandin Analog.

BIMATOPROST

MeSH Pharmacological Classification · 1 件

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Absorption, Distribution and Excretion · 4 件

This drug is absorbed systemically when administered to the eye. A study was performed on 15 healthy volunteers and bimatoprost ophthalmic solution 0.03% was administered once daily for 14 days. The mean Cmax was approximately 0.08 ng/mL and AUC0-24hr was approximately 0.09 on days 7 and 14 of the study. By 10 minutes, peak blood concentration was achieved. Bimatoprost was not detectable at 1.5 hours after administration in most subjects. The maximum blood concentration in a study of 6 healthy volunteers was determined to be 12.2 ng/mL. Steady state was reached in the first week of dosing. One drug label mentions that onset of decreased intraocular pressure occurs approximately 4 hours after the first administration and the peak effect occurs in the range of 8-12 hours. Bimatoprost effects may last up to 24 hours.

One pharmacokinetic study of bimatoprost in 6 healthy volunteers determined that 67% of the administered dose was found to be excreted in the urine while 25% of the dose was recovered in the feces.

The volume of distribution at steady state is 0.67 L/kg.. It penetrates the human cornea and sclera.

The clearance was measured to be 1.5 L/hr/kg in healthy subjects receiving IV administration of bimatoprost dosed at 3.12 ug/kg.

Cellular LocationsCytoplasm
応用分野 · 4 件

用途プロスタマイド受容体(PM 受容体)に作用し、眼房水の排出を促進する ことで、眼圧低下作用を示します。

説明Bimatoprost was first introduced in the US and Brazil as Lumigan, an ophthalmic solution (0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, a proven risk of glaucomatous visual field loss. Bitamoprost is a new agent belonging to the PGF2α analog class of prostamides launched in this indication after latanoprost, the most efficaceous topical medication currently available. This synthetic fatty acid amide can be prepared by esterification of 17- phenyl-18,19,20-trinorprostaglandin F2α followed by ethylamidation. Bimatoprost, as related prostamides, is devoid of typical activities associated with PGF2,, analogs; it exhibits a unique pharmacological profile in contracting the feline iris sphincter with an EC50 of 34 nM without interacting with any known prostanoid receptors. Thus it mimics the action of endogenous prostamides on specific receptors that lower IOP by increasing aqueous humor outflow through both pressure-insensitive and pressure-sensitive pathways without reducing humor formation. In a 3-month controlled clinical trial of efficacy and safety in patients with elevated IOP, bimatoprost demonstrated lower mean intraocular pressures at every time point throughout the study, as well as a good tolerance and systemic safety profile compared to latanoprost.

使用Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes. It ha

一般的な説明Bimatoprost (Lumigan) is supplied as a sterile 0.03%ophthalmic solution in 2.5- and 5.0-mL sizes. The recommendeddosage of bimatoprost is limited to one drop intothe affected eye once daily in the evening. Increased usagemay decrease its beneficial effect. If used concurrently withother IOP-lowering drugs, a waiting period of 5 minutesshould separate administrations.

上流・下流製品情報

下流製品

(5E)-ビマトプロスト